University of Electronic Science and Technology of China (UESTC)
Sichuan, Chengdu, 611731, China
NCT Number: NCT04715737
The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.
Looking for future studies?
Notify Me18 year–30 year
Male
Interventional
Not applicable
Sichuan, Chengdu, 611731, China
Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administration of vasopressin (20IU) intranasally
Administration of oxytocin (24IU) intranasally
Administration of placebo intranasally
Time frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Time frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between social-specific error rates of saccade/antisaccade between the vasopressin, oxytocin and placebo treatment conditions
Time frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Time frame: Time Frame: 45 minutes - 100 minutes after treatment
Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin, oxytocin and placebo treatment conditions
University of Electronic Science and Technology of China
Other
The Differential Effects of Intranasal Vasopressin and Oxytocin on Attention Control
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06605300
Diabetes Insipidus, Endocrine System Diseases
Chengdu, China
View Trial DetailsNCT04890470
Diabetes Insipidus, Endocrine System Diseases
Sichuan, China
View Trial DetailsNCT01327027
Antisocial Personality Disorder, Diabetes Insipidus
Portland, Maine, United States
View Trial DetailsNCT01566539
Diabetes Insipidus, Endocrine System Diseases
Atlanta, Georgia, United States
View Trial Details